Penetration of Titanium Dioxide Nanoparticles through Slightly Damaged Skin in Vitro and in vivo
Source abstract
Abstract
Purpose Titanium dioxide nanoparticles (TiO 2 -NPs) have been widely developed for versatile use, but the potential risk form their skin exposure is still unclear. To evaluate this risk, the skin penetration of TiO 2 -NPs is necessary to be understood first. The aims of this study are to investigated the penetration of TiO 2 -NPs through slightly damaged skin and intact skin in vitro and in vivo. Methods TiO 2 -NPs with a diameter of 20 nm was labeled with 125 I. The skin of rat was treated with 2% SLS solution and obtained as slightly damaged skin. The 125 I labeled TiO 2 -NPs ( 125 I-TiO 2 -NPs)solution and 0.9% PS solution were added into the donor chamber and receptor chamber of static diffusion cells which clamped the skin at the middle of two half-cells, respectively. During 24 hours, samples were extracted from the receptor chamber and counted for 1 min using γ-counter to detect the radioactivity. The skin penetration of TiO 2 -NPs in vitro was expressed as the percentage of radioactivity of receptor chamber solution compared with total radioactivity in the donor chamber. Thereafter, the 125 I-TiO 2 -NPs was exposed to the rats. After 1 day and 3 days, the blood and tissues of rats were harvested, weighed and counted for 1 min using γ-counter to detect the tissue radioactivity. The skin penetration of TiO 2 -NPs in vivo was expressed as the percentage dose per gram tissue (% dose/g). Results In the skin penetration experiment in vitro, the radioactivity of receptor chamber solution through damaged skin was higher than that of through intact skin and was about 2% radioactivity of donor chamber on 24 h. In the skin penetration experiment in vivo, the radioactivity of blood and tissues of rats after exposing to 125 I-TiO 2 -NPs solution though damaged skin or intact skin were less than 0.05% dose/g on 1 d and quickly declined on 3 d. The skin penetration rates of TiO 2 -NPs through slightly damaged skin and intact skin in vitro and vivo were lower than the rate of free 125 I in the TiO 2 -NPs solution. Conclusions The TiO 2 -NPs could not penetrate through the damaged skin or intact skin both in vitro and in vivo. It suggested that the TiO 2 -NPs should be safe when it was applied and contacted with skin.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Nanotechnology research and applications · Radiation Dose and Imaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Stomatology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai - China
Department of Clinical Medicine, Medical School, Huzhou University, Huzhou - China
References (27)
Show source-provided references
1. 10.1079/BJN2004127610.1079/BJN20041276 ↗
2. 10.1289/ehp.733910.1289/ehp.7339 ↗
3. 10.1117/1.213801710.1117/1.2138017 ↗
4. 10.1007/s00204-007-0253-y10.1007/s00204-007-0253-y ↗
5. 10.1038/444267a10.1038/444267a ↗
6. 10.1093/toxsci/kfi33910.1093/toxsci/kfi339 ↗
7. 10.1038/nbt87510.1038/nbt875 ↗
8. 10.1146/annurev.publhealth.031308.10015510.1146/annurev.publhealth.031308.100155 ↗
9. 10.1016/S0014-5793(97)01356-210.1016/S0014-5793(97)01356-2 ↗
10. 10.1002/smll.20080079810.1002/smll.200800798 ↗
11. 10.1289/ehp.1021610.1289/ehp.10216 ↗
12. 10.1016/j.tox.2006.11.00210.1016/j.tox.2006.11.002 ↗
13. 10.1016/j.tox.2008.09.01410.1016/j.tox.2008.09.014 ↗
14. 10.1016/j.toxlet.2006.12.00110.1016/j.toxlet.2006.12.001 ↗
15. 10.1159/00013107810.1159/000131078 ↗
16. 10.1016/j.jaad.2009.02.05110.1016/j.jaad.2009.02.051 ↗
17. 10.1016/S0928-0987(01)00167-110.1016/S0928-0987(01)00167-1 ↗
18. 10.2131/jts.35.10710.2131/jts.35.107 ↗
19. 10.1016/S0169-409X(02)00120-510.1016/S0169-409X(02)00120-5 ↗
20. 10.1016/0190-9622(92)70060-S10.1016/0190-9622(92)70060-S ↗
21. 10.1007/s00403-005-0555-y10.1007/s00403-005-0555-y ↗
22. 10.1159/00024782210.1159/000247822 ↗
23. 10.1016/j.ijpharm.2003.09.02110.1016/j.ijpharm.2003.09.021 ↗
24. 10.1179/oeh.2000.6.2.14310.1179/oeh.2000.6.2.143 ↗
25. 10.1016/j.tox.2008.09.02510.1016/j.tox.2008.09.025 ↗
26. 10.1159/00009616710.1159/000096167 ↗
27. 10.1159/00013108010.1159/000131080 ↗